Cell Genesys and Medarex Report Follow-Up Data From a Phase 1 Combination Therapy Trial With GVAX Immunotherapy for Prostate Cancer and Ipilimumab (MDX-010) Antibody
...trial in patients with advanced prostate cancer receiving Cell Genesys' GVAX immunotherapy for prostate cancer administered in combination with ipilimumab (MDX-010), a fully human anti-CTLA-4 antibody that is being jointly developed by Medarex and Bristol-Myers Squibb Company. The new data reported...
News & Articles (Drugs.com) · More like this

New Ipilimumab Survival Data in Patients with Metastatic Melanoma Presented at American Society of Clinical Oncology Annual Meeting
...June 2 /CNW Telbec/ - Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) announced yesterday preliminary survival data for ipilimumab (10 mg/kg monotherapy), an investigational oncology immunotherapy, in previously-treated patients with advanced metastatic melanoma. Results...
Clinical Trial Results (FDA) · More like this

Updated Survival Data from Three Phase 2 Ipilimumab Studies Showed Almost Half of Previously Treated Metastatic Melanoma Patients Alive Beyond One Year
...2008 - Bristol-Myers Squibb Company (NYSE: BMY) and Medarex, Inc. (NASDAQ: MEDX) today announced updated survival data from three Phase 2 studies of ipilimumab in patients with advanced metastatic melanoma (Stage III or IV) who had previously been treated. Study results show that approximately half...
Clinical Trial Results (FDA) · More like this

Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
...June 05, 2007 /PRNewswire-FirstCall/ -- Medarex, Inc. and Bristol-Myers Squibb Company today presented results from multiple clinical studies of ipilimumab (MDX-010), an investigational immunotherapy, for patients with advanced melanoma. The results demonstrated an anti-tumor response in some patients...
Clinical Trial Results (FDA) · More like this

Cell Genesys Reports Updated Results From Phase 1 Clinical Trial of GVAX Immunotherapy for Prostate Cancer Used in Combination With Ipilimumab
...today announced interim data from the ongoing Phase 1 clinical trial of GVAX immunotherapy for prostate cancer used in combination with ipilimumab in patients with advanced prostate cancer. Updated data reported includes median follow-up of approximately 22.3 months on the 12 patients enrolled...
Clinical Trial Results (FDA) · More like this

Having trouble finding what you want?

• Try browsing our A-Z List of Drug Names or our Medical Encyclopedia.
• Try posting your query on the Drugs.com Community Discussion Boards
• Drug Interactions Checker provides detailed information on drug-drug and drug-food interactions.
• Pill Identifier will help you identify an unknown pill by imprint code or shape/color.
• Image Search is helpful if you want to know what a certain pill looks like.
• News, FDA Approvals or In The Pipeline may help if the drug you are looking for is a new drug.